Ipsen (Paris:IPN) and Medicis (NYSE:MRX) today announced the submission of the Biologics License Application (“BLA”) for Reloxin®1 to the U.S. Food and Drug Administration (“FDA”). Upon FDA’s acceptance of the Reloxin® filing, Medicis will pay Ipsen approximately $25 million in accordance with the agreement between the parties. In March 2006, Ipsen granted Medicis the rights to develop, distribute and commercialize Ipsen’s botulinum toxin product in the United States, Canada and Japan for aesthetic use by physicians. Medicis anticipates a response from FDA in approximately 10 months following FDA’s receipt of the Reloxin® submission.
